Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | GABRP | O00591 | 5/20 | 0.51 |
| ▸ | GABRD | O14764 | 5/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2216831 | 0.89 | CNR2 (0.80) | CNR2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2215015 | 0.88 | CNR2 (0.71) | CNR2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2213176 | 0.87 | CNR2 (0.71) | CNR2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2214559 | 0.84 | CNR2 (0.66) | CNR2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL4175899 | 0.83 | CNR2 (0.71) | CNR2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2214952 | 0.81 | HPGD (0.54) | CNR2ALDH1A1MAPTKDM4ETSHR | |
| SCHEMBL4175894 | 0.81 | CNR2 (0.55) | CNR2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL15865703 | 0.81 | KDM4E (0.58) | CNR2ALDH1A1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL2212394 | 0.81 | CNR2 (0.94) | CNR2ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL600437 | 0.80 | CNR2 (1.00) | CNR2ALDH1A1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | claimed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | claimed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | CNR2 156/4885ALDH1A1 324/4885MAPT 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.